WILL G. RYAN, M.D.; THEODORE B. SCHWARTZ, M.D.
To the editor: In 1969 we first reported in this journal the effect of mithramycin on Paget's disease of bone (1). Since then we have treated approximately 150 patients with Paget's disease ranging in age from 40 to 80 years with generally favorable results. During this interval we have observed after single 10-day courses of mithramycin the development of generalized lymphosarcoma with lymphosarcoma cell leukemia in one patient and chronic lymphocytic leukemia in two. All were men in their sixties at time of treatment. The lymphosarcoma was discovered within a few months after mithramycin therapy, and the chronic lymphocytic leukemias
RYAN WG, SCHWARTZ TB. Mithramycin and Malignancy. Ann Intern Med. ;94:279. doi: 10.7326/0003-4819-94-2-279_2
Download citation file:
Published: Ann Intern Med. 1981;94(2):279.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use